Hodgkin Lymphoma in Jordan; A Retrospective Analysis of 477 Cases in King Hussein Cancer Centre

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4862-4862 ◽  
Author(s):  
Alaa Addasi
Keyword(s):  
Retrospective Analysis ◽  
Hodgkin Lymphoma ◽  
Hodgkin’S Lymphoma ◽  
Conflicts Of Interest ◽  
Hodgkin's Lymphoma ◽  
Cancer Center ◽  
Pathological Features ◽  
Female Ratio ◽  
Non Hodgkin Lymphoma ◽  
Paraffin Block

Abstract Abstract 4862 BACKGROUND Jordan is a small country with an estimated mid year population in 2008 of 5 850 000, 3015000 of whom are males and 2 835 000 are females (male: female ratio 1.06: 1). (Department of Statistics Jordan, 2008). About 12.7 % of the population is under 5 years old, and 37.3 % under 15 years old. 11%if the population are 15–19 year old, with a M:F ratio 1.06:1 as well) Only 3.3 % of the total population is above the age of 65 years old (sex ratio of 1.01 male per 1 female in this age group). According to the Jordan Cancer Registry Report for 2008, Lymphoma is the fourth most common Cancer in the country. A total of (4606 ) new cases of cancer were recorded among Jordanians in the year 2008, 333 (7.2%) of whom had a diagnosis of lymphoma.111 (2.4%) were diagnosed as Hodgkin's lymphoma (HL), and 222 (4.8%) as Non Hodgkin Lymphoma(NHL). OBJECTIVE In this study, we aim to characterize some of the clinico-pathological features of Hodgkin lymphoma in Jordan by analyzing the data available for patients referred to King Hussein Cancer Center over a seven year period. PATIENTS AND METHODS A retrospective analysis was conducted of adults (>18 years) lymphoma patients referred to KHCC, between 1/1/2003 and 31/12/2010. Clinical features and histological subtypes were prospectively established for all patients registered in the Lymphoma Service Database. Pathology review and original paraffin block were mandated for all patients. RESULTS Over the 8 year period of 2003–2010,1329 lymphoma patients were referred to KHCC and registered in the Lymphoma Service Database, of whom 477 (35.9%) were diagnosed with Hodgkin's lymphoma. Among this group all 477 patients were adults 18 years or older (100%), as children are treated in a different department. The median age was 35 years, (with an age range of 18–77), and 5% of patients were above the age of 60. 290 (61 %) of the patients were males, 187 (39%) were females, with a male to female (M:F) ratio of 1.55:1. 276 (57.8%) of the HL cases had a diagnosis of nodular sclerosis Hodgkin lymphoma (HDNS), making it the most common histological subtype. 120(25.2%) had mixed cellularity Hodgkin lymphoma (HDMC), 9 (1.9%) had lymphocyte-rich Hodgkin lymphoma (HDLR), and 6 (1.2%) had lymphocyte-depleted Hodgkin (HDLD). Nodular lymphocyte predominance Hodgkin lymphoma (NLPHD) cases were 33, and constituted 6.9% of the HL cohort. CONCLUSION Hodgkin lymphoma appears to constitute a bigger share of the lymphoma burden in Jordan, as opposed to Europe and the US. Clinico-pathological features, however, appear to be closer to those described in Western countries, with similar incidence of HDNS, and HDMC subtypes, but possibly with less incidence of HDLR and HDLD subtypes. Disclosures: No relevant conflicts of interest to declare.

Secondary Neoplasms Subsequent to Berlin-Frankfurt-Muenster (BFM) Therapy of Non-Hodgkin Lymphoma of Childhood: Significantly Higher Risk for Patients with Lymphoblastic Lymphoma Compared to Other NHL-Subtypes.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 232-232 ◽  
Author(s):  
Olga Wachowski ◽  
Martin Zimmermann ◽  
Birgit Burkhardt ◽  
Olaf Determann ◽  
Ulrike Meyer ◽  
...  
Keyword(s):  
Risk Factor ◽  
Brain Tumors ◽  
Hodgkin Lymphoma ◽  
Cumulative Incidence ◽  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
Cumulative Risk ◽  
Lymphoblastic Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin Lymphoma

Abstract We evaluated the rate and type of second malignant neoplasms (SMN) after BFM treatment of children with Non-Hodgkin lymphoma (NHL). Between January 1981 and February 2003 2451 patients (pts) <15 years (y) of age at diagnosis were enrolled into the subsequent trials NHL-BFM 81, 83, 86, 90, and 95. Pts with lymphoblastic lymphoma (LBL) (n=547) or non-anaplastic peripheral T-cell lymphoma (n=97) received acute lymphoblastic leukemia (ALL)-type therapy including cumulative doses of cyclophosphamide (max. 3g/m2), daunorubicine/doxorubicin (max. 280mg/m2), but, except few pts, no etoposide. Prophylactic cranial radiotherapy (CRT) was given in stage III/IV (omitted in NHL-BFM95). Pts with mature B-cell neoplasms (n=1597), or anaplastic large cell lymphoma (n=210) received B-type therapy, consisting of 2–8, 5-day courses including cumulative doses of cyclophosphamide (max. 7g/m2), ifosfamide (max. 8g/m2), doxorubicine max. 150mg/m2 (in trial 81 max. 200mg/m2), and etoposide (max. 1.4g/m2). CRT was omitted since trial NHL-BFM86. With a median follow-up of 6.9 (range 0.2–22.6) years the probability of survival at 15 y was 83+1%. By June 2005, 47 SMN were documented, including 16 acute myeloid leukemias/myelodysplastic syndromes (AML/MDS), 11 NHL, 2 ALL, 1 Hodgkin’s lymphoma, 7 brain tumors, and 10 other SMN. All SMN occurred in first remission after a median time of 2.9 (range: 0.4–12.3) years from diagnosis of NHL. The cumulative incidence of SMN at 15 y was 4.0% (95% confidence interval [CI]: 1.9%–6.1%) for the total group. The cumulative incidence of SMN was significantly higher among pts with LBL receiving ALL-type therapy (6.3% at 15 y [95%CI: 2.4%–10.3%] (13 AML/MDS, 2 NHL, 3 brain tumors, and 3 other SMN), as compared to pts with other NHL-entities receiving B-type therapy (3.4% at 15 y [95% CI: 0.5–6.4%] (3 AML/MDS, 9 NHL, 2 ALL, 1 Hodgkin’s lymphoma, 4 brain tumors, and 7 other SMN), p=0.002. There was no significant difference of cumulative incidence of SMN in pts who received CRT compared to pts not receiving CRT. However, 5 of 7 pts, who developed brain tumor, received CRT of 12–24 Gy. Also, there was no significant correlation between the incidence of SMN and the cumulative doses of drugs, except for anthracyclines. For pts receiving a cumulative dose of anthracyclines of >160mg/m2 (almost exclusively pts with LBL receiving ALL-type therapy) the cumulative risk for SMN at 15 y was 6.5% (95% CI: 1.5-11.5%), as compared to 2.0% (95% CI: 1.1–2.9%) for pts with lower doses, p=0.007. Exposure to etoposide was not a risk factor for secondary AML/MDS (11 of 16 pts with sec. AML/MDS did not receive etoposide). In a Cox regression analysis only diagnosis of LBL remained a significant risk factor for SMN (RR 2.5, 95% CI 1.4–4.4). Our analysis revealed a cumulative risk for SMN of 4% at 15 y after successful treatment of childhood NHL. The cumulative incidence of SMN was significantly higher in LBL-pts than in other pts. AML/MDS were the most frequent SMN following LBL while second lymphoid malignancies were the most frequent SMN following non-LBL.

scholarly journals Profile of Paediatric Malignancies in Yangon Children Hospital: A Three Year Study

2016 ◽  
Vol 2 (3_suppl) ◽  
pp. 52s-52s
Author(s):  
Ssu Wynn Mon ◽  
Aye Aye Khaing ◽  
Han Win ◽  
Tint Myo Hnin ◽  
Ye Myat Thu ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Conflicts Of Interest ◽  
Lymphoblastic Leukemia ◽  
Germ Cell Tumour ◽  
Hodgkin's Lymphoma ◽  
Paediatric Cancer ◽  
Female Ratio ◽  
Cancer Data ◽  
Childhood Malignancies ◽  
Oncology Unit

Abstract 13 Although paediatric malignancy is one of the major health threats worldwide and its incidence is on rise, little is known about its epidemiology. In Myanmar also, reports on the pattern of childhood cancer are very few. Reliable paediatric cancer data are essential for assessing the magnitude of this problem and for qualified paediatric cancer care. This study aimed to describe the relative frequencies of various paediatric malignancies in Yangon Children Hospital (YCH) according to age and sex. This hospital based retrospective study covered all children aged 0 to 14 years with confirmed malignancies using 3 years hospital records of Haematology-Oncology Unit, from January 2012 to December 2014. Total 609 patients were diagnosed as cancer during study period. Among them, 379 cases (62.2%) were haematological malignancies and 230 cases (37.8%) were solid tumours. Acute lymphoblastic leukemia (27.5%), Acute myeloblastic leukemia (14.3%), Non-Hodgkin's lymphoma (14%) and Retinoblastoma (9.7%) were four most common childhood malignancies. Wilm's tumour (6.8%), Neuroblastoma (6.7%), Germ cell tumour (4.1%) and Rhabdomyosarcoma (3.6%) were also common. Less common were brain tumours (2.1%), Hodgkin's lymphoma (1.5%) and Burkitt's lymphoma (1.0%). Prevalence was higher in boys (58.6%) than girls (41.4%) with male to female ratio 1.5:1. About half (50.9%) of the patients were younger than 5 years and prevalence was less in more than 10 years age group (15.7%). As the data were collected from hospital, findings from this study might not be the representation of our national statistics. But as Haematology-Oncology unit, YCH is one of the two paediatric oncology centers in Myanmar and patients from most regions attend this hospital for specialist care, these findings could reflect the burden of paediatric malignancy in our country. AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST: No COIs from the authors.

scholarly journals The Relationship Between Clinical Manifestation and Histopatological Result in Non- Hodgkin Lymphoma: RSUD Dr. Soetomo Surabaya

2021 ◽  
Vol 5 (4) ◽  
pp. 134-138
Author(s):  
Glazydia Juwita Rachma ◽  
Ugroseno Yudho Bintoro ◽  
Mia Ratwita Andarsini ◽  
Novira Widajanti
Keyword(s):  
Hodgkin Lymphoma ◽  
Hodgkin’S Lymphoma ◽  
Clinical Manifestations ◽  
Hodgkin's Lymphoma ◽  
Major Public Health Problem ◽  
Non Hodgkin Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Degree Of Malignancy ◽  
The Relationship

Non-Hodgkin's lymphoma is a major public health problem with over 14.1 million people are diagnosed with it (2012). In the same year there were 8.2 million deaths due to cancer. The purpose of this study was to determine the relationship between clinical manifestations and the degree of malignancy based on histopathological features in patients with Non-Hodgkin's Lymphoma. This study used a retrospective analytical method with a cross-sectional approach using the patient's medical record at RSUD Dr. Soetomo, Surabaya who was diagnosed with Non-Hodgkin Lymphoma from 1st January 2015 to 31st December 2017. In this study, there were 139 samples include those criteria, with a greater number of male samples (62.6%) compared to women (37.4%). This study showed that 49.3% of patients with non- Hodgkin's lymphoma in RSUD Dr. Soetomo with clinical manifestations without symptoms actually experience malignancy with a high degree, this showed that clinical manifestations without symptoms are not always associated with a low level of malignancy. Then, based on the Chi Square test results obtained p-value of 0.289 (>0.05), so there was no significant relationship between clinical manifestations and the degree of malignancy. Keywords: lymphoma; manifestation; histopatological

scholarly journals Survival Improvement in Therapy Related Myeloid Neosplasm ? a Single Center Analysis of 428 Patients

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 4006-4006
Author(s):  
Khalil Saleh ◽  
Christophe Willekens ◽  
Jean Edouard Martin ◽  
Myriam Kossai ◽  
Nadine Khalifé-Saleh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hodgkin Lymphoma ◽  
Conflicts Of Interest ◽  
Best Supportive Care ◽  
Primary Diagnosis ◽  
Study Data ◽  
Cancer Center ◽  
Complex Karyotype ◽  
Non Hodgkin Lymphoma ◽  
Radiotherapy Alone

Abstract Therapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) arise after cytotoxic chemotherapy and/or radiotherapy administered for a prior neoplasm and have a dismal outcome (median survival of 8 months in the largest series published including 306 patients (pts), Smith, Blood 2003). Recent registry data suggested a continued increase in survival in AML (Derolf, Blood 2009) and we wondered whether this was also observed in the setting of t-AML/ MDS. All pts with a t-AML/MDS diagnosed and/or treated for their prior neoplasm at Gustave Roussy Cancer Center between July 1986 and 2016 were included in this retrospective study. Data regarding pts' demographics, primary diagnosis and treatment, latency time, cytogenetic, treatment and outcome were collected. The diagnosis of t-AML/MDS was based on the WHO 2016 classification. t-AML were classified based on cytogenetic results as favorable, intermediate and adverse according to international classification, t-MDS based on IPSS score as favorable (Low, Int-1) and adverse (Int-2 and High). 428 pts were analyzed. The median age at diagnosis of t-AML/MDS was 56.4 years with a female predominance (60%). 224/428 (52.3%) pts had t-AML, 204/428 (47.7%) t-MDS. The most common primary malignancies were breast cancer (24%), non-Hodgkin lymphoma (15%), Hodgkin lymphoma (HL) (9%) and ovarian cancer (9%). Occurrence of t-AML/MDS following HL represented 26.6% of t-AML/MDS cases between 1986-96 comparing to 4 % between 2006-16 whereas breast cancer rose from 16% to 45%. Prior treatments included chemotherapy alone in 137/428 pts (32%), radiotherapy alone in 61 pts (14%) and both in 230 pts (54%). At diagnosis of t-AML/MDS, 295 pts (69%) were in complete remission (CR) of their prior neoplasm, 29 (7%) had a stable and 104 (24%) a progressive disease. Median interval between primary cancer and t-AML/MDS was 5 years (4.3 and 5.7 years for t-AML and t-MDS respectively, (p=0.03)). Furthermore, delay to develop t-AML/MDS after radiotherapy alone was longer compare to chemotherapy or both (6.1, 5.1 and 4.3 years, respectively (p=0.0087)). In the t-AML subgroup, 47% of pts presented unfavorable cytogenetic (including complex karyotype (20%) and 11q23 abnormalities (16.9%)), 26% intermediate and 26% favorable cytogenetic (core binding factor mutations (12.7%), t(15;17) (13.3%)). In the t-MDS subgroup, 78% of pts were considered adverse; complex karyotype, chromosome 7 and 5 abnormalities were found in 40.8%, 46.7% and 28.9% respectively. Pts received intensive chemotherapy (including 41 allografts), low dose chemotherapy (including 74 treatments with hypomethylating agents) and best supportive care in 42%, 24% and 34% respectively. The median overall survival (OS) was 10.6 months and the 5-year survival was 19.1% (Figure 1A). The 5-year OS of patients in CR of their prior neoplasm was 25.5% compared to 3.65 and 0% for pts with progressive and stable disease, respectively (p<0.001). 5-year OS was not statistically different between t-AML and t-MDS subgroups (23.3% vs 13.5%) and between hematologic or oncologic malignancies as primary diagnosis (12.6% vs 21.1%). Pts with favorable risk t-AML had better 5-year survival compared with patients with intermediate or unfavorable risk disease (55.5% vs 20% vs 12.1% respectively, p<0.001). In addition, favorable t-MDS was associated with better 5-year OS compared to adverse t-MDS (34.9% vs 6.6%, p<0.001). We next compared OS of pts diagnosed for their t-AML/MDS after or before July 2001. A trend for better OS for pts diagnosed in the last 15 years was observed (21.5% vs 15.1%, p=0.39). Interestingly outcome of t-AML patients with favorable subtype significantly improved over the last 15 years (68.8% vs 25%, p=0.03, Figure 1B) which was not the case for other cytogenetic subgroups and for t-MDS, especially pts with adverse prognosis (4.6% vs 3.9%, p=0.92). Pts who received allograft had a trend for better OS in the last 15 years (52.8% vs 21.5% p=0.2). t-AML/MDS are still associated with a low 5-year OS (19.1%) but our results are upper than previous publications. However, a significant improvement of survival in favorable t-AML was observed during the past 30-years, with a trend for pts who benefit from allograft. In addition to improve treatment for t-MDS pts, detection of the disease at the earliest stage is a real challenge to improve their survival. Disclosures No relevant conflicts of interest to declare.

Primary gastrointestinal non-Hodgkin’s lymphoma in two Hungarian regions

2009 ◽  
Vol 150 (35) ◽  
pp. 1649-1653
Author(s):  
Balázs Kollár ◽  
Péter Rajnics ◽  
Béla Hunyady ◽  
Erika Zeleznik ◽  
János Jakucs ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Hodgkin Lymphoma ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

A felnőttkori non-Hodgkin-lymphoma előfordulása az elmúlt évtizedekben jelentősen nőtt. A betegcsoport nagyon heterogén, változatos klinikai és morfológiai megjelenéssel. A legjellemzőbb nodalis érintettség mellett gyakoriak az extranodalis formák, amelyek leggyakrabban a gastrointestinalis traktust, a központi idegrendszert és a bőrt érintik. A gastrointestinalis traktus non-Hodgkin-lymphomáinak kezelési stratégiája változott az elmúlt évtizedben, a kemoimmunoterápia háttérbe szorította a korábban jóval gyakrabban végzett sebészeti beavatkozásokat. Módszerek: A szerzők Kaposváron, a Kaposi Mór Oktató Kórházban és Gyulán, a Pándy Kálmán Megyei Kórházban kezelt 48, gastrointestinalis traktust érintő non-Hodgkin-lymphomás betegük adatait mutatják be. A betegek közül 27 nő és 21 férfi, átlagéletkoruk 67,8 év. A leggyakoribb lokalizáció a gyomor ( n = 26), a leggyakoribb szövettani típus diffúz nagy B-sejtes lymphoma (DLBCL) volt. A betegek rizikófaktorait a nemzetközi prognosztikai index (IPI) alapján állapították meg. Negyvenhat beteg kapott kemoimmunoterápiás kezelést, 6 esetben érintett mezős sugárkezelés, 3 esetben Helicobacter pylori -eradikáció, 4 betegnél gyomorreszekció történt. Eredmények: Az összes beteg 68%-ában sikerült komplett, 13%-ában parciális remissziót elérni, 19% nonreszponder volt. A nemzetközi prognosztikai index alapján a betegek többsége az alacsony, illetve magas intermedier rizikócsoportba tartozott (IPI-átlag: 2,68). A tápcsatorna felső szakaszát érintő lymphomás betegek prognózisa volt a legjobb (IPI: 2,0), ugyanakkor a gyomorlymphomás betegeknél volt a legmagasabb a komplett remisszió aránya (73%). Következtetés: Kemoimmunoterápiával a betegek gyógyulási esélyei javultak az elmúlt évtizedben, a gastrointestinalis traktust érintő non-Hodgkin-lymphomák jelentős hányada meggyógyítható. Az IPI a legelfogadottabb mutató a non-Hodgkin-lymphoma prognózisának megítélésére. A komplett remisszióba jutott betegek prognosztikai indexe volt a legalacsonyabb, de az IPI-n kívül egyéb tényezők is befolyásolhatják a kezelésre adott választ.

scholarly journals FREQUENCY OF BONE MARROW INVOLVEMENT IN CASES OF LYMPHOMA: A HOSPITAL BASED OBSERVATIONAL STUDY

2020 ◽  
pp. 1-3
Author(s):  
Surbhi Mahajan ◽  
Subhash Bhardwaj ◽  
Poonam Sharma
Keyword(s):  
Bone Marrow ◽  
Hodgkin Lymphoma ◽  
Hodgkin’S Lymphoma ◽  
Bone Marrow Involvement ◽  
Hodgkin's Lymphoma ◽  
Classical Type ◽  
Low Grade ◽  
High Grade ◽  
Intermediate Grade ◽  
Non Hodgkin Lymphoma

Background: In patients with lymphoma, bone marrow involvement is definite evidence of disseminated disease and hence assessment of bone marrow status in these patients provides important information for decisions regarding treatment. Aim: To determine frequency of bone marrow involvement in cases of lymphoma. Results: Out of 60 histologically confirmed lymphoma patients, 51(85%) patients were of Non Hodgkin’s lymphoma and 9 (15%) patients were of Hodgkin’s lymphoma. International working formulation was followed to classify Non Hodgkin Lymphoma into low, intermediate and high grade. The low grade Non Hodgkin lymphoma cases comprised of 41.18% (21/51), high grade 39.21% (20/51) and intermediate grade 19.61% (10/51) cases. Out of 9 Hodgkin lymphoma (HL) cases, 8 (88.9%) were of classical type and there was a single case (11.1%) of lymphocytic predominant Hodgkin’s lymphoma. 25 (41.7%) cases showed bone marrow infiltration by the atypical lymphomatous cells. Bone marrow involvement was seen in 47.05% (24/51) cases of NHL. Among Non Hodgkin lymphoma cases, maximum involvement was seen in low grade NHL 57.14% (12/21) followed by intermediate grade NHL 50% (5/10) & minimum was seen in high grade NHL 35% (7/20). Conclusion: Thorough examination of bone marrow in lymphoma patients can increase the diagnostic accuracy as it may be the single most important finding in a patient with an otherwise localized disease thereby contributing to the prognosis and appropriate treatment modalities.

Hodgkin's Lymphoma in the Portuguese Population – Epidemiological and Pathological Characterization.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4634-4634
Author(s):  
Maria Gomes Silva ◽  
Susana Esteves ◽  
Inês Barbosa ◽  
José Cabeçadas
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Conflicts Of Interest ◽  
The Other ◽  
Hodgkin's Lymphoma ◽  
Portuguese Population ◽  
Mixed Cellularity ◽  
Female Ratio ◽  
Western Countries ◽  
Nodular Sclerosis ◽  
Epidemiological Characteristics

Abstract Abstract 4634 Classical Hodgkin's lymphoma (cHL) has a bi-modal age distribution in the Western World, with a peak in young adults and another over 50 yo. The nodular sclerosis subtype predominates, mainly in the first group. In contrast, in developing countries, higher incidences in childhood and elderly populations and a predominance of the mixed cellularity subtype is observed. The epidemiological characteristics of the disease in Portugal, an European country with an elevated number of immigrants from West Africa, have not been reported. We aimed to determine the histological distribution and sex and age-specific incidence of Hodgkin's lymphoma in the Portuguese population and compare it to the Western pattern. For that, we performed a retrospective analysis of all cases registered at the Portuguese Cancer Registry-South Region (a network comprising 29 hospitals representative of the country's epidemiology) between 1999 and 2003 and determined the sex and age-specific incidence (cases/100 000 inhabitants) and exact 95% confidence intervals. Population data was obtained from the National Institute of Statistics. To investigate a possible recent trend for higher incidences in older ages, as has been described in other western countries, we used the Standardized Incidence Ratio (SIR) for comparison between 2006-2007 and 1999-2000. A total of 615 cases were diagnosed in the south of Portugal between 1999 and 2003, with a male/female ratio of 1.24:1. The age specific incidence revealed a bi-modal distribution with a peak at 15-24 yo (4.41/100 000 inhabitants) and another at 65-74 yo (2.94/100 000/inhabitants). The incidence of the disease in individuals older than 55 in 1999-2000 and 2006-2007 (3.56 and 3.81 in men, respectively, and 1.89 and 2.87 in women, respectively) increased by 25% (SIR:1.25, 95% CI:1.02-1.52, p=0.03 two-sided Mid-P exact test). This was mainly attributable to an increased incidence in women older than 55 (SIR:1.50; 95% CI:1.12-1.99, p=0.007), whereas in men the incidence remained stable (SIR:1.07, 95% CI:0.80-1.41, p=0.60). Since the registry data did not include histology in 27% cases, we systematically reviewed the pathological specimens of 229 consecutive patients diagnosed in our tertiary cancer care center during the same period (1999-2003). These patients were younger than the ones diagnosed in the other network hospitals (median age 29 and 40.5 yo, respectively, p<0,001 Mann-Whitney test), with a similar male to female ratio. 92% were subclassifiable. From these, 5% had nodular lymphocyte predominance HL and 95% (199 cases) cHL. Nodular sclerosis accounted for 89% of cHD and mixed cellularity for 6.5% of cases. From the other 233 registry cases classified as cHD, 78% were also nodular sclerosis. In Portugal, where immigration from African countries could have lead to different disease characteristics, epidemiological patterns of HL are similar to the Western ones. Similarly to reports from other western countries, we observed a trend for an increased incidence in the elderly. A higher than expected proportion of nodular sclerosis subtype was found in a subgroup analysis, which may be related to the younger age reported in this subgroup. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document